This lecture was part of a CME accredited symposium: How to address residual risk post ACS: LDL-c, dyslipidemia, and inflammation held at ESC 2016 in Rome

Educational information

The educational objectives of this symposum were to:

• Discuss the potential of current and future strategies targeting inflammation in reducing residual risk in post ACS patients
• Outline current ongoing clinical development programs aimed at testing the inflammation hypothesis of cardiovascular disease
• Understand the unmet need for additional LDL-C-lowering therapies beyond current optimal statin-based therapy as a strategy for addressing lipid-related CV risk in patients post ACS
• Describe the potential impact of PCSK9-based therapies in development in patients who require additional LDL-C reduction
• To review the clinical significance of additional lipid lowering pathways, such as ezetimibe, in the management of patients with ACS
• Understand the implications of new guidelines for lipid management

Disclosures

Professor Chris Packard, MD: R&D Director, NHS Greater Glasgow & Clyde Health Board, Honorary Professor of Vascular Biochemistry, University of Glasgow - Consultant Clinical Scientist, Dept of Biochemistry NHS Greater Glasgow & Clyde Health Board

Funding

This EBAC accredited symposium was funded by unrestricted educational grants received from Novartis, MSD, Amgen

View slides of this lecture